文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

T 细胞具有超敏阈感知抗原密度的回路。

T cell circuits that sense antigen density with an ultrasensitive threshold.

机构信息

Cell Design Institute, Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.

Center for Cellular Construction, University of California San Francisco, San Francisco, CA, USA.

出版信息

Science. 2021 Mar 12;371(6534):1166-1171. doi: 10.1126/science.abc1855. Epub 2021 Feb 25.


DOI:10.1126/science.abc1855
PMID:33632893
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8025675/
Abstract

Overexpressed tumor-associated antigens [for example, epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2)] are attractive targets for therapeutic T cells, but toxic "off-tumor" cross-reaction with normal tissues that express low levels of target antigen can occur with chimeric antigen receptor (CAR)-T cells. Inspired by natural ultrasensitive response circuits, we engineered a two-step positive-feedback circuit that allows human cytotoxic T cells to discriminate targets on the basis of a sigmoidal antigen-density threshold. In this circuit, a low-affinity synthetic Notch receptor for HER2 controls the expression of a high-affinity CAR for HER2. Increasing HER2 density thus has cooperative effects on T cells-it increases both CAR expression and activation-leading to a sigmoidal response. T cells with this circuit show sharp discrimination between target cells expressing normal amounts of HER2 and cancer cells expressing 100 times as much HER2, both in vitro and in vivo.

摘要

过表达的肿瘤相关抗原(例如表皮生长因子受体(EGFR)和人表皮生长因子受体 2(HER2))是治疗性 T 细胞的有吸引力的靶标,但嵌合抗原受体(CAR)-T 细胞可能与低水平表达靶抗原的正常组织发生有毒的“脱靶”交叉反应。受天然超敏反应回路的启发,我们设计了一个两步正反馈回路,允许人细胞毒性 T 细胞根据抗原密度的 S 形阈值来区分靶标。在该回路中,用于 HER2 的低亲和力合成 Notch 受体控制用于 HER2 的高亲和力 CAR 的表达。因此,HER2 密度的增加对 T 细胞具有协同作用——它既增加了 CAR 的表达又增加了其激活——导致 S 形反应。该回路中的 T 细胞在体外和体内均能在表达正常量 HER2 的靶细胞与表达 100 倍 HER2 的癌细胞之间进行锐利区分。

相似文献

[1]
T cell circuits that sense antigen density with an ultrasensitive threshold.

Science. 2021-3-12

[2]
Development of chimeric antigen receptor-modified T cells for the treatment of esophageal cancer.

Tumori. 2021-8

[3]
Preclinical efficacy of a HER2 synNotch/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplification.

Mol Ther. 2024-8-7

[4]
[Specific cytotoxicity of a novel HER2-based chimeric antigen receptor modified T lymphocytes against HER2-positive tumor cells].

Zhonghua Bing Li Xue Za Zhi. 2017-10-8

[5]
HER2-targeting CAR-T cells show highly efficient anti-tumor activity against glioblastoma both in vitro and in vivo.

Genes Immun. 2024-6

[6]
Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.

Clin Cancer Res. 2019-7-1

[7]
A Functional Screening Strategy for Engineering Chimeric Antigen Receptors with Reduced On-Target, Off-Tumor Activation.

Mol Ther. 2020-12-2

[8]
Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies.

Cancer Lett. 2020-8-1

[9]
PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor.

Mol Ther. 2011-7-19

[10]
Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2 Breast Cancer Metastasis to the Brain.

Clin Cancer Res. 2017-10-23

引用本文的文献

[1]
Constructing the cure: engineering the next wave of antibody and cellular immune therapies.

J Immunother Cancer. 2025-8-25

[2]
Tracing the development of CAR-T cell design: from concept to next-generation platforms.

Front Immunol. 2025-7-17

[3]
Directed evolution of LaccID for cell surface proximity labeling and electron microscopy.

Nat Chem Biol. 2025-8-1

[4]
Glioblastoma at the crossroads: current understanding and future therapeutic horizons.

Signal Transduct Target Ther. 2025-7-9

[5]
Research progress on HER2-specific chimeric antigen receptor T cells for immunotherapy of solid tumors.

Front Immunol. 2025-5-21

[6]
Sensitizing solid tumors to CAR-mediated cytotoxicity by lipid nanoparticle delivery of synthetic antigens.

Nat Cancer. 2025-5-16

[7]
SynNotch CAR-T cell, when synthetic biology and immunology meet again.

Front Immunol. 2025-4-16

[8]
Tailoring CAR surface density and dynamics to improve CAR-T cell therapy.

J Immunother Cancer. 2025-4-29

[9]
dFLASH; dual FLuorescent transcription factor activity sensor for histone integrated live-cell reporting and high-content screening.

Nat Commun. 2025-4-7

[10]
Post-transcriptional modular synthetic receptors.

Nat Chem Biol. 2025-3-28

本文引用的文献

[1]
Human chimeric antigen receptor macrophages for cancer immunotherapy.

Nat Biotechnol. 2020-3-23

[2]
Cascaded amplifying circuits enable ultrasensitive cellular sensors for toxic metals.

Nat Chem Biol. 2019-3-25

[3]
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

N Engl J Med. 2018-12-1

[4]
TumGrowth: An open-access web tool for the statistical analysis of tumor growth curves.

Oncoimmunology. 2018-8-1

[5]
CAR-T cells: the long and winding road to solid tumors.

Cell Death Dis. 2018-2-15

[6]
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.

N Engl J Med. 2018-2-1

[7]
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

N Engl J Med. 2017-12-28

[8]
Phase I Study of Chimeric Antigen Receptor-Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers.

Clin Cancer Res. 2017-11-14

[9]
Chimeric antigen receptor T-cell therapies for lymphoma.

Nat Rev Clin Oncol. 2017-8-31

[10]
The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity.

Cancer Immunol Immunother. 2017-11

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索